Certara, Inc.
No enriched coverage for $CERT in the last 7 days.
No SEC Form 4 filings for $CERT in the last 30 days.
See all $CERT insider activity →Certara, Inc. reported Q2 2026 updates on its shift to specialist, scientist-led sales and a divestiture of its regulatory and medical writing business. Software revenue is 53% of total, up from 40% two years ago. Full-year revenue guidance is 0% to 4%, with adjusted EBITDA margin guided at 29% to 31%. Net loss from continuing operations was $6.1M. A new $50M share repurchase was authorized.
Certara (CERT) reported Q2 2026 revenue of $93.3 million, up 1% YoY, with software revenue $48.8 million (+4%) and services $44.5 million (-3%). Total bookings were $98.3 million (+1%). Adjusted EBITDA was $26.2 million (28.1% margin). 2026 guidance: revenue $367-$382 million and adjusted EPS $0.31-$0.36. The company completed a divestiture and is integrating AI, and announced NVIDIA partnership.
Certara, Inc. (CERT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 q22026earningsreleaseex99.htm EX-99 Document Exhibit 99.1 Certara Reports Second Quarter 2026 Financial Results A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million
Recent CERT coverage spans earnings, financial news and corporate actions.
Guidance and margin range reset around the divestiture, with buyback authorization adding a near-term capital return signal.
Guidance and margin framing around the divestiture, plus AI-driven software momentum and buyback authorization, are the key drivers for CERT’s near-term valuation debate.
Q2 results were roughly in line with expectations, with software growth offset by services weakness and higher operating costs tied to contingent consideration remeasurement and reorg costs.
The filing signals a leadership change in commercial leadership, with severance and a defined transition period, which can affect near-term execution and investor sentiment.
The delay is tied to optimization work, with management saying it should not materially impact the ESIA submission timeline.
alphai scores every news story that mentions CERT with an AI model for sentiment and relevance, and aggregates insider trades from Certara, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Certara, Inc. reported Q2 2026 updates on its shift to specialist, scientist-led sales and a divestiture of its regulatory and medical writing business. Software revenue is 53% of total, up from 40% two years ago. Full-year revenue guidance is 0% to 4%, with adjusted EBITDA margin guided at 29% to 31%. Net loss from continuing operations was $6.1M. A new $50M share repurchase was authorized.
7 min readCertara (CERT) reported Q2 2026 revenue of $93.3 million, up 1% YoY, with software revenue $48.8 million (+4%) and services $44.5 million (-3%). Total bookings were $98.3 million (+1%). Adjusted EBITDA was $26.2 million (28.1% margin). 2026 guidance: revenue $367-$382 million and adjusted EPS $0.31-$0.36. The company completed a divestiture and is integrating AI, and announced NVIDIA partnership.
7 min readCertara, Inc. (CERT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 q22026earningsreleaseex99.htm EX-99 Document Exhibit 99.1 Certara Reports Second Quarter 2026 Financial Results A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million
6 min readCertara, Inc. (CERT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001827090 0001827090 2026-07-30 2026-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readCerrado Gold said it will extend the completion timing of the Mont Sorcier bankable feasibility study to incorporate optimization work. The company plans mine-plan changes to reduce strip ratio, review tailings dam and CAPEX/OPEX amid inflation, and assess a 65% vs 67% iron concentrate trade-off. It expects ESIA filing in Q2 2027 and permits around year-end 2028.
4 min readCertara said it is integrating Nvidia’s BioNeMo Agent Toolkit into its AI drug development platform, adding agentic frameworks to support tasks across dosing optimization, clinical-data analysis, ADMET evaluation and regulatory evidence. Silo Pharma’s subsidiary QwikAgents joined Nvidia’s Developer Program to expand its autonomous AI agent platform. NVDA shares were up; Certara and Silo were down at publication.
4 min readCertara (Nasdaq: CERT) said it is partnering with NVIDIA to integrate NVIDIA’s BioNeMo Agent Toolkit into Certara’s open AI platform. The toolkit is positioned as an agentic framework that can use Certara’s biosimulation models, datasets, and regulatory expertise to generate life-sciences insights across drug development. The company did not provide financial figures.
3 min readCertara, Inc. (CERT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001827090 0001827090 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readCertara, Inc. (NASDAQ:CERT) held its Q1 2026 earnings call, reporting an EPS of $0.09 against expectations of $0.11. CEO Jon Resnick outlined strategic initiatives to drive long-term growth, including divesting the medical writing business, reorganizing into two distinct growth areas (MID3 and ACE), enhancing AI integration with a Chief AI Officer, and forming key partnerships with NVIDIA and Altasciences. The company updated its full-year 2026 revenue guidance to reflect the divestiture, expecting $395 million to $405 million, and anticipates improved performance in the second half of the year.
4 min readCertara (CERT) announced Q1 revenue of $106.9 million, exceeding analyst expectations. The company is implementing strategic initiatives to enhance operational effectiveness and drive sustainable growth, including divesting its Medical Writing segment, focusing on two primary growth areas, and accelerating its AI program. Though Certara has a moderate GF Score™ of 68, indicating long-term potential, investors are advised to approach with caution due to challenges in profitability and the recent divestiture.
2 min read
